Murray M G, Kuhn R J, Arita M, Kawamura N, Nomoto A, Wimmer E
Department of Microbiology, State University of New York, Stony Brook 11794-8621.
Proc Natl Acad Sci U S A. 1988 May;85(9):3203-7. doi: 10.1073/pnas.85.9.3203.
Poliovirus exists as three stable serotypes (PV-1, PV-2, and PV-3). These viruses display three antigenic sites each, designated N-AgI, N-AgII, and N-AgIII. When mice are immunized with poliovirus, N-AgI is the major neutralization antigenic site for PV-3, whereas N-AgII and N-AgIII are immunodominant over N-AgI for PV-1. To study the relationship between structure and antigenicity, a hybrid virus was constructed in which N-AgI of PV-1 was replaced by N-AgI of PV-3. PV-3- and PV-1-specific antisera, including those elicited by PV-3 in primates, neutralized the hybrid virus. Injection of the hybrid virus into rabbits or into primates resulted in the production of antisera that neutralized both PV-1 and PV-3. The data show that sequence replacement at N-AgI of poliovirus is compatible with viral proliferation, an observation useful for the development of multivalent picornavirus vaccines.
脊髓灰质炎病毒以三种稳定的血清型（PV-1、PV-2和PV-3）存在。这些病毒各自显示三个抗原位点，分别命名为N-AgI、N-AgII和N-AgIII。当用脊髓灰质炎病毒免疫小鼠时，N-AgI是PV-3的主要中和抗原位点，而对于PV-1，N-AgII和N-AgIII比N-AgI具有免疫优势。为了研究结构与抗原性之间的关系，构建了一种杂交病毒，其中PV-1的N-AgI被PV-3的N-AgI取代。PV-3和PV-1特异性抗血清，包括由灵长类动物中的PV-3引发的抗血清，均可中和该杂交病毒。将杂交病毒注射到兔子或灵长类动物体内会产生能中和PV-1和PV-3的抗血清。数据表明，脊髓灰质炎病毒N-AgI处的序列替换与病毒增殖相容，这一观察结果对多价微小核糖核酸病毒疫苗的开发很有用。
